Why It Matters
Hearing: Senate Special Committee on Aging, "Foreign Dependence and America’s Drug Supply"
Date and Time: March 11, 2026
The U.S. relies on foreign nations for 75 percent of its essential drug supply, with China alone supplying upwards of 80 percent of active pharmaceutical ingredients in generics. This is a dependence that poses immediate threats to seniors and all Americans.
What’s at stake:
- Supply chain disruption: A major committee investigation concludes that if China or India halted drug exports, the U.S. would face medication rationing within weeks.
- Safety risks: Foreign-produced generics carry a 54 percent greater risk of serious adverse events — including hospitalization and death — compared to U.S.-made equivalents. The FDA has repeatedly granted waivers to facilities previously banned for safety violations.
- National security: Potential adversaries control critical medications, and lawmakers have raised concerns about possible noncompliance with forced labor laws by suppliers in China’s Xinjiang region.
Chairman Rick Scott (R-FL) has made this a signature issue, sponsoring the bipartisan Mapping America’s Pharmaceutical Supply (MAPS) Act to create supply chain visibility and identify vulnerabilities. The hearing caps months of investigation, including prior sessions on drug labeling transparency, domestic manufacturing, and unsafe foreign generics.
Broader Context
The MAPS Act would direct HHS to maintain lists of essential medicines and conduct risk assessments, while mandating the Defense Department report on military reliance on Chinese drug components. Congressional investigations have documented cases where the FDA granted exemptions to foreign facilities with prior safety violations — including Sun Pharma, a major Indian manufacturer that continued importing drugs despite repeated violations. Lawmakers have also flagged potential Uyghur Forced Labor Prevention Act noncompliance among Xinjiang-based suppliers.
Between The Lines
The bipartisan nature of the MAPS Act signals cross-party agreement on the problem’s severity. Ranking Member Kirsten Gillibrand (D-NY) has not taken a prominent public position on the specific issue. Scott’s prior investigative report, "Protecting Seniors’ Access to Essential Medications," frames the stakes: halted exports from China or India would force rationing within weeks.
Competitive Landscape
A review of lobbying disclosures found no records of lobbying activity on foreign drug dependence or China’s role in pharmaceutical supply chains — notable given the policy implications. Advocacy may be occurring through non-traditional channels as congressional momentum builds. Foreign-reliant generic manufacturers, including Sun Pharma, face direct scrutiny over quality control and compliance costs. Domestic reshoring advocates have been far more visible before the committee.
The Bottom Line
The March 11 hearing is the culmination of a sustained Senate investigation into a concrete national vulnerability. With 75 percent of essential drugs sourced abroad, a 54 percent elevated safety risk from foreign generics, and no lobbying pushback on record, Chairman Scott has room to advance the MAPS Act with bipartisan support — and pressure on the FDA and industry to respond.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article